FDA Expands Clearance of MRI-Guided AI Platform for Deep Brain Stimulation and Lesioning Techniques
Utilizing a new machine learning model, the OptimMRI software may improve radiosurgery applications and lesioning techniques such as MRI-guided focused ultrasound through enhanced targeting of the inferolateral part of the ventral intermediate nucleus (VIM).
The Food and Drug Administration (FDA) has granted an expanded 510(k) clearance for the artificial intelligence (AI)-powered OptimMRI software, which may bolster targeted deep brain stimulation (DBS) of neurological disorders such as essential tremor.
The expanded clearance is for the addition of a new machine learning model in the OptimMRI platform that is geared toward targeting of inferolateral part of the ventral intermediate nucleus (VIM). The improved targeting may help enhance accuracy with MRI-guided focused ultrasound (MRgFUS) lesioning techniques and radiosurgery applications, according to RebrAIn, the developer of OptimMRI.
The MRI-guided AI software OptimMRI features a newly FDA-cleared machine learning model that reportedly offers improved targeting of inferolateral part of the ventral intermediate nucleus (VIM), which may facilitate enhanced accuracy of deep brain stimulation for neurological disorders such as essential tremor. (Image courtesy of Adobe Stock.)
The company noted the OptimMRI platform previously garnered FDA clearance in January 2024 for machine learning models targeting VIM and subthalamic nucleus (STN) regions for DBS applications.
“The United States market represents the largest opportunity to enable personalized targeting for neurological disorders such as essential tremor. The ability to offer AI clinical targeting to neurosurgical suites will open many collaborations nationwide,” noted David Caumartin, the chief executive officer of RebrAIn.
Emmanuel Cuny, M.D., and Nejib Zemzemi, M.D., the co-founders of RebrAIn, will discuss VIM targeting during a session at the World Society for Stereotactic and Functional Neurosurgery (WSSFN) conference in Chicago on September 5. For more information, visit www.wssfn2024.org .
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
